% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Crespo:298625,
      author       = {E. Crespo and L. R. Loureiro and A. Stammberger and L.
                      Hoffmann and N. Berndt and A. Hoffmann and C. Dagostino and
                      K. E. G. Soto and L. Rupp and C. Arndt and M. Schneider and
                      C. Ball$^*$ and M. Bachmann$^*$ and M. Schmitz$^*$ and A.
                      Feldmann$^*$},
      title        = {{R}ev{CAR}-mediated {T}-cell response against
                      {PD}-{L}1-expressing cells turns suppression into
                      activation.},
      journal      = {npj precision oncology},
      volume       = {9},
      number       = {1},
      issn         = {2397-768X},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-00325},
      pages        = {42},
      year         = {2025},
      abstract     = {Applying CAR T-cell therapy to treat solid tumors is
                      especially challenging due to the immunosuppressive tumor
                      microenvironment (TME). While our modular RevCAR system
                      enhances the safety and controllability of CAR T-cell
                      therapy, effectively targeting solid tumors remains
                      difficult. Since PD-L1 is an immune checkpoint frequently
                      upregulated by cancer cells and their microenvironment, it
                      is a relevant target for solid tumors. Here, we introduce a
                      novel PD-L1 RevTM capable of redirecting RevCAR T-cells to
                      specifically target and kill PD-L1-expressing tumor cells,
                      becoming activated and secreting pro-inflammatory cytokines.
                      This is shown in vitro with monolayer and 3D models,
                      including patient-derived cultures, and in vivo.
                      Furthermore, we demonstrate in vitro and in vivo an
                      AND-gated targeting of cells simultaneously expressing PD-L1
                      and another tumor-associated antigen by the Dual RevCAR
                      system. Our findings suggest that RevCAR-mediated targeting
                      of PD-L1 could be a promising therapeutic approach for
                      modulating the TME and improving solid tumor treatment.},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39924591},
      doi          = {10.1038/s41698-025-00828-6},
      url          = {https://inrepo02.dkfz.de/record/298625},
}